Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Diageo appoints Deirdre Mahlan as interim CFO

(Sharecast News) - Diageo said on Wednesday that it has appointed Deirdre Mahlan as interim chief financial officer with effect from 18 August. The drinks giant said Mahlan brings extensive spirits industry and Diageo knowledge as well as broad consumer goods experience in both executive and board positions.

Her career includes 27 years at Diageo and predecessor companies, including serving as Diageo's CFO from 2010 to 2015.

Most recently, she served as interim president, chief executive officer and chairperson of The Duckhorn Portfolio ahead of its sale to Butterfly Equity.

Interim CEO Nik Jhangiani said: "Deirdre brings extensive spirits and functional expertise to the interim chief financial officer role, complemented with deep knowledge of Diageo and its operations.

"I am delighted that she has agreed to return on an interim basis and I have full confidence that she will provide invaluable guidance to our teams, and partner with me as we deliver on our Accelerate programme to drive long term sustainable growth."

Earlier this month, Diageo announced that chief executive Debra Crew had stepped down with immediate effect, by mutual agreement.

Crew took over in June 2023 after the sudden death of long-time and well-respected CEO Ivan Menezes, having joined the company as a non-executive director in 2019 and later served as president of Diageo North America and subsequently as group chief operating officer.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.